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INTRODUCTION 
 
Urinary Tract Infections (UTIs) are one of the most common bacterial 
infections in humans, both in the community and the hospital settings affecting 
approximately  150 million  people worldwide  annually which  results in  more than 
6 billion US dollars  loss to the global economy1, 2. Incidence of UTI in India is 
50,000/ million persons per year and accounts for 1-2 % of patients in primary care3.   
About 50% of all women experiences atleast 1 episode of UTI during their life 
time.Recurrent infection occurring in 20 – 30 % of the females results in high 
morbidity and mortality4.   
The incidence of UTI is greatly influenced by age, sex, anatomical and 
functional abnormalities of the urinary tract.  Infected urine in pregnant women 
stimulates an immunological and inflammatory response in the unborn leading to 
many complications such as premature babies and IUGR as well as Hypertension and 
renal failure ending fatally from cradle to grave5.   
More than 90% of acute UTI in community is acquired infection caused by 
Escherichia coli  and 10 – 20 % by CONS especially Staphylococcus saphrophyticus  
which is the second most common cause in young sexually active women and 5% or 
less by other Enterobacteriaceae and Enterococci. In complicated cases of UTI 
resulting from anatomical obstruction and catheterization, the most common causative 
agents are E. coli followed by Klebsiella pneumoniae, Proteus mirabilis, 
Pseudomonas aeruginosa, and Enterococcus spp6, 7. 
  In general, the urinary tract infections are treated mostly with broad spectrum 
Cephalosporins, Flouroquinolones and Aminoglycosides.  The Cephalosporins which 
includes, Cephelexin, Cefotaxime, Ceftazidime etc., are cell wall inhibitors and are 
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used commonly for treating infections caused by Gram negative organism.             
The Fluroquinolones consisting of Norfloxacin, Ciprofloxacin, Oflaxicin, 
Sparfloxicin, Levofloxicin etc., are antibiotics which act by inhibiting the activity of 
DNA gyrase and Topoisomerase the enzymes that are essential for bacterial DNA 
replication.  The aminoglycosides antibiotics include Gentamicin, Kanamicin and 
Amikacin etc., and they act by inhibiting bacterial protein synthesis8.  
The E. coli would have developed resistance to antimicrobial agents and the 
phenomenon is increasing both in outpatients and hospitalized patients7, 9. Among 
members of the Enterobacteriaceae family, resistance to β- lactams has been reported 
to be associated with ESBL and Amp C β- lactamase 10. ESBL producing organisms 
hydrolyze oxyimino β- lactams like Cefotaxime, Ceftriaxone, Ceftazidime and 
Monobactams but have no effect on Cephamicins, Carbapenems and related 
compounds 11. Amp C β- lactamases are clinically important because they confer 
rsistance to narrow -, expanded -, and broad spectrum Cepahalosporins, β- lactam- β- 
lactamase inhibitor combinations and Aztreonam12. 
ESBL producing E. coli in patients with UTI has been observed by several 
workers; its prevalence was variously reported from 28 to 67.5%13-17, 7. The 
prevalence of ESBL producing Klebsiella has been reported to be more than 55%18.  
Production of β- lactamase is frequently plasmid encoded and bears clinical 
significance.  Plasmids responsible for ESBL and Amp C β- lactamase production 
frequently carry genes encoding resistance to other drugs also and therefore antibiotic 
options in the treatment of β- lactamases producing organisms are extremely 
limited19.   
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 The major concern in the occurrence of ESBL and Amp C β- lactamases is 
the spread of ESBL and Amp C β-lactamases positive bacteria within hospitals, which 
may lead to outbreaks or endemic situation20 - 23. In addition, as therapeutic choices 
are much limited, it is equally difficult to treat the infections caused by ESBL and 
Amp C β-lactamase positive organisms19.  Many clinical laboratories currently test   
E. coli and Klebsiella spp. for production of ESBL’s but do not attempt to detect 
plasmid mediated Amp C  β- lactamases12. It is necessary to investigate the 
prevalence of ESBL positive and Amp C β- lactamase strains in hospitals, so as to 
guide the clinician for better therapy.  
The prevalence of antimicrobial resistance pattern may vary between 
geographical areas.  However, the publications available on the susceptibility pattern 
of bacterial isolates in UTI and ESBL prevalence in South East zone of Tamil Nadu 
are scanty.  Hence, the present study is under taken to find out the frequency of the 
uropathogens, their susceptibility pattern and ESBL production in order to facilitate 
effective management of UTI.  
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OBJECTIVES 
 
1. To find out the bacteriological profile of Urinary Tract Infections. 
2. To identify the prevalence of Escherichia coli and Klebsiella among the 
isolated organisms. 
3. To see the sensitivity pattern for the pathogens those are isolated. 
4. To screen ESBL production among the isolated E. coli and Klebsiella. 
5. To detect Amp C β- lactamase production among the isolated E. coli and 
Klebsiella. 
6. To compare the sensitivity pattern among the isolated ESBL producing and 
non ESBL producing E. coli and Klebsiella.  
7. To provide guidelines to the clinician regarding the treatment of UTI caused 
by ESBL and Amp C β- lactamase producing   E. coli and Klebsiella. 
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REVIEW OF LITERATURE 
 
Historical Review 
 
Individual cases of UTI were recorded in antiquity as early as 1412.  The first 
case of UTI was recorded by John Arden in Britain. Later in 1863, Pasteur has 
recognized urine as a good culture media for bacteria and Roberts (1881) 24 related the 
presence of bacteria in the urine to symptoms, but very little progress was made in 
exploring the relationship until quantitative assessments of the number of bacteria in 
the urine of patients with urinary tract infection were carried out by many authors25, 26, 
27. In 1995, Quantitative bacterial counting over 105 bacteria per ml was regarded as 
true (or) significant bacteriuria by Kass concept 28. 
 
Classification of UTI 29 
I.  Lower UTI  
a. Urethritis:  Infection of the urethra which present as dysurea and frequency.  
b. Cystitis: Infection of the bladder with features of dysurea, frequency, urgency, 
supra pubic tenderness, etc. 
c. Acute urethral syndrome: young sexually active women with dysurea, 
frequency and urgency but yield organisms less than 105 cfu/ml. 
d. Prostatitis: Infection of the prostate. 
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II.  Upper UTI 
a. Pyelonephritis:  Inflammation of the kidney, parenchyma, calices and           
     Pelvis caused by bacterial infection. 
b. Ureteritis: Rare, usually due to tuberculosis. 
 
Types of UTI 29 
1. Uncomplicated UTI refers to infection in a structurally and neurologically 
normal urinary tract. 
2. Complicated urinary tract infection refers to infection in a urinary tract with 
functional (or) structural abnormalities. 
3. Relapse:  Recurrence of bacteriuria with the same infecting micro organism that 
was present before therapy was started due to persistence of the organism in the 
urinary tract. 
4. Reinfection: Recurrence of bacteriuria with a micro organism different from the 
original infecting bacterium. 
5. Asymptomatic bacteriuria:   Isolation of significant count of bacteria from a 
person without signs and symptoms of UTI. 
 
Epidemiology of Urinary Tract Infection30 
  Acute community acquired UTI’s are very common.  In female, 1-3 per cent 
School girls affected by UTI and then increases markedly with the onset of sexual 
activity and it is most common among women between 20 – 50 years of age.  In the 
male population, acute symptomatic UTI’s occur in first year of life often in 
association with urologic abnormalities; thereafter UTI’s are unusual in male patients 
under the age of 50. 
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Pathogenesis of Urinary Tract Infection: 
A thorough knowledge on the normal anatomy of urinary tract is essential to 
understand the pathogenesis of UTI. 
 
Normal Anatomy          Route of Transmission of infection 
 
           Source 31 
 
Route of infection  
Urine is normally a sterile fluid.  Bacteria can invade and cause UTI via two 
major routes. Ascending route is the most common route of infection in females. 
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Catheterization and cystoscopy also can cause UTI in both sexes by ascending route.  
Enteric Gram Negative Bacteria (GNB) and other organisms that originate in Gastro 
Intestinal Tract (GIT) must be able to colonise the vaginal cavity and periurethral 
area.  Once they gain access to the bladder, multiply and pass up to the ureter and 
kidneys.32, 33,34  5 % of UTI is due to haematogenous spread as a result of bacteraemia 
e.g. Staphylococcus aureus and Salmonella typhi. 
 
Host defence against UTI 34, 29 
1. Urine itself is inhibitory to anaerobic bacteria and the low pH, high 
osmolarity, high organic acid content and constant flushing action of urine 
inhibit the bacterial colonization. 
2. Valve like membranes at the junction of  bladder and ureter that prevents back 
flow of urine. 
3. Immune system – Lipo Poly Saccharides of bacteria activates the host cell and 
releases cytokines such as TNF-  α  and IFN -   γ, activation of complement 
system. 
4. Tamm-Horsfall Protein (or) uromucoid serves as anti adherence factor by 
binding to E.coli expressing type I fimbriae. 
5. Defensins – group of small antimicrobial peptides produced by macrophages, 
neutrophils and cells in the urinary tract and attached to the bacterial cell, 
eventually kill the bacteria. 
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Predisposing factors 35, 29 
 
                              Source 31, 36 
 
The following are the factors that favours development of UTI 29, 35 
¾ Any abnormality of the urinary tract that obstructs or slows the flow of urine e.g. 
Tumour, stricture and in men enlarged prostate can obstruct the urine flow and 
make infection difficult to treat. 
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¾ UTI occur in small percentage of infants due to congenital abnormality that 
required surgery. 
¾ People on Immuno suppressive state – Diabetes Mellitus. 
¾  UTI is more common in females because of the shorter urethra that opens in to 
the moist introitus which is colonised by bacteria. For many women, sexual 
intercourse seems to precipitate UTI. Women who are using diaphragm and (or) 
spermicides as a contraceptive are more likely to develop UTI than with other 
forms of contraception. 
¾ Pregnant women (2-8%) are more susceptible to UTI’s attributed to impairment of 
urine flow partly due to hormonal changes (decreased ureteral tone, decreased 
ureteral peristalsis and temporary incontinent of vesico ureteric valve) and partly 
due to pressure on the urinary tract37,  38 20 – 30 per cent of women with 
asymptomatic bacteriuria progress to pyelonephritis. 
¾ Post menopausal women due to oestrogen deficiency and with prolapsed uterus.  
¾ Patients with neurogenic bladder e.g., spinal cord injury, tabes dorsalis, multiple 
sclerosis and diabetes mellitus (or) bladder diverticulum. 
 
Virulence factors for E. coli 29, 39 
Fimbria, which binds on urothelium persist within the urinary tract.  Three 
types of fimbriae are Type ‘S’ fimbriae (S FA-1), Type ‘P’ fimbriae and Type ‘Dr’ 
fimbriae.   
Other factors are Siderophores, Toxins – Haemolysin subdivided in α - lysine 
which lysis the RBC and β Lysine which lysis the RBC’s, lymphocytes and inhibit the 
phagocytosis, Cytotoxic necrotising factor – CNF 1,2, Uropathogenic strain specific 
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proteins (USP), Protectins, TIR Domain containing proteins (tcp C), Intimin, 
Colonising factor – CFA I, II, III. 
 
Virulence factors for Klebsiella  
Four factors of virulence in Klebsiella spp. are Capsular antigen, Type I and 
Type III pili, serum resistance LPS and siderophore. 
Treatment 
             UTI is commonly treated with Cephalosporins, Fluroquinolones                              
and Amino glycosides. Among these third generation Cephalosporins are most widely 
prescribed because of its broad spectrum of activity, low toxicity, ease of 
administration and its favourable pharmacokinetic profile29. Because of their 
extensive use they also developed resistance to many organisms especially ESBL 
producing organism26.   
 
Extended Spectrum β Lactamase (ESBL) 
 Antibiotic era started with discovery of penicillin by Alexander Flemming in 
1928  40. Use of Penicillin started in 1941.  Emergence of penicillin resistance is 
identified in Staphylococcus aureus due to plasmid encoded    β-lactamase.  First 
plasmid mediated β-lactamase in gram negative organisms- TEM-1 was described in 
early 1960’s.  It was first isolated in Escherichia coli from a patient Temoniera in 
Greece and the gene responsible for it was named after him.  It spread to other genera 
soon.  Another common plasmid mediated β-lactamase found in Klebsiella 
pneumoniae and Escherichia coli are SHV-1 (Sulph Hydryl in Variable).  Over the 
last 20 years many new β - lactam antibiotics have been developed which were 
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resistant to hydrolytic action of β - lactamases but, because of indiscriminate use, 
these antibiotics also became resistant. 
 To overcome it, around 1980, 3rd generation cephalosporins are  also called 
broad spectrum Cephalosporins were introduced. Because of their extensive use, they 
also became resistant.  
In Germany during 1983, isolates of Klebsiella pneumoniae and other 
Enterobacteriaceae were found to produce a plasmid-determined β-lactamase that 
hydrolyzed Cefotaxime, as well as other newer 3rd generation of Cephalosporins. This 
new β-lactamase, called SHV-2 was derived from a mutation in the well-known SHV-
1β-lactamase commonly found in Klebsiella  37 and as they lead to resistance of 
extended spectrum cephalosporin they are called extended spectrum    β-lactamases29. 
 
β- Lactam antibiotics: 40  
They are antibiotics having a β - lactam ring. It comprises of Penicillins, 
Cephalosporins, Monobactams, Carbapenems.  All the β-lactam antibiotics have         
β-lactam ring in common which is made of 3 carbon atoms and one nitrogen atom. 
The other rings vary in respect of each group of antibiotics. 
1. Penicillins: 
The structure of Penicillin is  
 
 
 
 
 
Types of Penicillin 
1. β-lactam ring 
2. Thiazolidone ring 
3. site where β-lactamase will act 
1 2
3
3
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I. Natural Penicillin  e.g., Penicillin G 
II. Semi synthetic Penicillin    
1. Acid resistant penicillin e.g., Penicillin V 
2. Penicillinase resistant Penicillin e.g., Methicillin, Oxacillin,Cloxacillin 
3. Extended spectrum Penicillin.  
a. Amino Penicillin e.g., Ampicillin, Amoxycillin 
b. Carboxy penicillin e.g., Carbenicillin 
c. Ureido Penicillin  e.g., Piperacillin, Mezlocillin 
 
2. Cephalosporins:  
 
 
 
 
 
Have β- lactam ring attached to six member sulfur containing dihyro thiazine 
ring. By addition of different side chains to dihyro thiazine ring a large number of 
semi-synthetic compounds have been produced. They are divided into four 
generations  
1st Generation Cephalosporins are active against streptococcus, Methicillin 
Sensitive Straphylococcus aureus (MSSA) and Gram Negative Bacteria (GNB) eg., 
Cephalothin, Cephalexin, Cefadroxil, Cefazolin. 
2nd Generation cephalosporin are having greater stability against β- lactamase 
inactivation and broader spectrum of activity to Gram Positive Cocci [GPC], GNB 
and anaerobes. Eg, Cefuroxime, Cefuroxime Axetil, Cefaclor, Cefoxitin. 
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  3rd Generation cephalosporin are having high degree of invitro potency to β 
lactamase  stability, broad spectrum of activity against  common GNB, anaerobes, 
good activity against streptococcus and less activity against Staphylococcus e.g., 
Cefotaxim, Ceftazidime, Cefixim, Cefoperazone ceftriaxone. 
 4th Generation cephalosporin are greater activity against GPC, 
Enterobacteriaceae and Pseudomonas.  e.g., Cefepime, Cefpirome. 
 
3. Monobactams:  
 
 
 
 
 
 
Monobactams have a monocyclic β - lactam ring and are resistant to                 
β - lactamase. They are active against gram negative bacteria but not against gram 
positive bacteria. e.g., Aztreonam. 
 
4. Carbapenems:  
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These drugs are structurally related to the β-lactam antibiotics. They are 
extremely potent and have very broad spectrum of activity. e.g., Imipenem 39  
 
Mechanism of Action of β-lactam antibiotics 40  
 The β-lactam antibiotics act by inhibiting cell wall synthesis of bacteria. 
Bacteria synthesise UDP – N – Acetyl muramic acid pentapeptide and UDP – N – 
Acetyl glucosamine.  Once Peptidoglycan residues are linked together and UDP is 
split off. Final step is cleavage of the terminal D-alanine of the peptide chains by 
Tran’s peptidases and cross linking between peptide chains of the neighbouring 
strands is formed.  β- lactam antibiotics inhibits trans peptidases so that cross linking 
is not formed. 40  
 
Mechanism of bacterial resistance to β-lactam antibiotics 40 
1. Enzymatic inhibition:  It is a plasmid mediated   e.g., β-lactamase 
2. Membrane impermeability in both chromosome and plasmid  mediated 
3. Alteration of target protein e.g., Penicillin binding protein. 
4. Enhanced efflux of the drug from the periplasmic space. 
 
The β- Lactamase 
This is a heterogeneous group of Penicillin recognizing proteins. They are 
members of a super family of active site serine proteases. They act by cleaving an 
amide bond of beta- lactam ring to form an acyl-enzyme complex. Any β-lactam 
antibiotic may be inactivated by these enzymes. There are about > 170 enzymes of 
this kind 41, 42.  
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Classification of beta- lactamases43 
Early classification scheme was developed by Richmon and Sykes based on 
substrate profile and the location of genes encoding the β-lactamases.  Modern 
scheme based on molecular structure was proposed by Ambler.  Class A, C, and D 
are serine β-lactamases, where as class B enzymes are metallo β-lactamase that 
requires zinc for activity.  
Recent classification of β-lactamases is by Bush-Jacoby – Medeiros scheme 
according to substrate profile and inhibition by clavulanic acid. 41 
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Table 1:      Bush–Jacoby–Medeiros Functional classification scheme for  
β- lactamases   (with Correlation to the Ambler Molecular Classification Scheme) 44, 43 
Group Enzyme Type Location 
Inhibition 
by 
Clavulanat
e 
Amblers 
Molecular 
Class 
No. of 
Enzymes 
Example 
1 Cephalosporinase 
Plasmid 
Chromosome 
No C 57 Resistance to all β – Lactams 
except Carbapenems 
2a Penicillinase 
Plasmid 
Chromosome 
Yes A 20 
 Staphylococcus aureus, S. 
Epidermidis; Enterocococus 
spp.; Penicillins 
2b Broad spectrum 
Plasmid 
Chromosome 
Yes A 16 
SHV-1 TEM-1,penicillins and 
cephalosporins 
2be 
Extended 
spectrum 
Plasmid 
Chromosome 
Yes A 81 
Klebsiella oxytoca, K1, TEM-3 , 
SHV-2, Penicillins and 
Cephalosporins 
2br Inhibitor resistant Plasmid Diminished A 13 
TEM-30, 
(IRT-2) 
2c Carbenicillinase 
Plasmid 
Chromosome 
Yes A 15 
AER-1 , PSE-1 , CARB-3, 
Cabenicillin 
2d Cloxacillinase 
Plasmid 
Chromosome 
Yes D or A 21 
Streptomyces cacaoi   OXA-
1,Cloxacilllin/Oxacilllin 
2e Cephalosporinase 
Plasmid 
Chromosome 
Yes A 19 
Proteus vulgaris, FEC-1, 
Cephalosporins 
2f Carbapenemase Chromosome Yes A 3 IMI-1 , NMC-A, Carbapenems 
3 Metalloenzyme 
Plasmid 
Chromosome 
No B 15 
Stenotrophomonas maltophila, 
L1, All β- lactams except 
monobactams    
4 Penicillinase 
Plasmid 
Chromosome 
No  7 Burkholderia cepacia 
 
 
The broad spectrum, plasmid mediated β - lactamases of Gram negative bacilli 
such as TEM-1 and SHV-1 produced by Class A were stable for many years.  
From 1980, a series of enzymatic variants appeared that had a broadened 
spectrum of activity against the newly developed β-lactam antibiotics.  These ESBLs 
were first found in Europe most commonly in Klebsiella species, less commonly in E. 
coli. The number of enzymes continues to increase. 
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 The new enzymes are located on TEM-1 and SHV-1 plasmids. But they might 
have been derived originally from a chromosomal enzyme.  Many of the new            
β-lactamases differ from each other only in single amino acid substitution but the 
changes have profound implications for clinical management of infectious diseases. 
 
Detection of β - lactamases45 
Detection of β-lactamases was done by various biochemical tests for the enzymes. 
This was by measuring Penicilloic acids which was produced when β-lactamases 
hydrolyse benzyl Penicillins. The acid production was detected by measuring the 
change in pH of an indicator dye (acidometric method), by exploiting the ability of 
Penicilloic acid to reduce iodine and reverse the formation of the blue colour when 
iodine complexes with starch (Iodometric method) and Chromogenic 
Cephalosporin method by using Nitrocephin. Nitrocephin was normally yellow but 
when the β-lactam ring was hydrolysed it turns red.  
 
β -lactamase inhibitors 43 
These compounds structurally resemble β-lactam antibiotics. They can bind to 
β-lactam antibiotics either reversibly or irreversibly protecting the antibiotics from 
destruction. They serve as suicide bombers utilizing all available enzymes. These 
compounds have weak antibacterial activity but are potent inhibitors of many 
plasmid-encoded and some chromosome encoded β-lactamases. Three important β-
lactamase inhibitors are Clavulanic acid, Sulbactam and Tazobactam. 
 
 
25 
 
Clavulanic acid show only low level of antibacterial action but when 
combined with β-lactam antibiotics, inhibition of bacteria is enhanced which are 
otherwise resistant to β-lactam antibiotics was noted.  Sulbactam has broader 
spectrum of inhibition but less potent.  Tazobactam is as potent as Clavulanic acid. 
 
Extended spectrum of β-lactamase 
Enzymes capable of hydrolyzing major β-lactam antibiotics including third 
generation Cephalosporins are called as extended spectrum beta- lactamases. 
 
Characteristics of ESBLs: 43 
They are mostly class- A Cephalosporinases carried on plasmids. 
They are more common in Klebsiella species followed by Escherichia coli described 
first in Germany and France. 
1) All enzymes active against   Cephalothin. 
2) Imipenem and Cefoxitin not hydrolysed. 
3) Comparative activity against Cefotaxime and Ceftazidine varies with 
enzymes. 
4) Some enzymes active against Aztreonam. 
5) Inhibition of activity by β-lactamase inhibitors can be demonstrated. 
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Table 2: Characteristics of the most common plasmid mediated “Wide Spectrum”    
               β- lactamases43 
Parameter Extended Spectrum  β-lactamase Amp C -lactamases 
Year  first reported 1983 1988 
Bacterial species 
affected 
Escherichia coli, Klebsiella 
pneumonia, Enterobacter spp., 
Salmonella spp., Proteus spp., 
Citrobacter spp., Morganella 
morganii, Serratia marcescens, 
Shigella dysenteriae, Pseudomonas 
aeruginosa, Burkholderia cepacia, 
Capnocytophaga ochracea and others 
E. coli, K. pneumonia, 
Salmonella spp, Citrobacter  
freundii, Enterobacter 
aerogenes, Proteus mirabilis 
Inhibition by inhibitors 
of β-lactamases 
(Clavulanate) 
Yes No 
Location of enzyme Plasmid Plasmid (derived from inducible 
chromosomal enzyme) 
Expression Constitutive Constitutive ( one expression) 
Indicator antibiotics Aztreonam, Ceftazidime, 
Ceftriaxone,Cefotaxime, Cefpodoxime 
Possibly Cefoxticin or Cefotetan 
Detection mechanism 
(screening) 
Indicator antibiotic with and without β-
lactamases  inhibitor 
 
Problematic : Use K. pnemoniae  
(no chromosomal Amp C 
enzyme ) as an “ institutional 
screen” 
Associated problems  Presence of an ESBL may be masked 
by coincident Amp C enzyme 
Difficult to differentiate plasmid 
from chromosomal enzyme 
Inoculum  effect Yes Yes 
Efficacy of apparently 
susceptible β-
lactamase in the 
presence of enzyme 
No Probably no 
Therapy with β-lactam  
/ β-lactamase inhibitor 
combinations 
Controversial No 
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Major risk factors for ESBL production   
Risk factors are prolonged stay in ICU, long term use of antibiotics, nursing 
home residency, severe illness, high rate use of Ceftazidime and other Third 
Generation Cephalosporins and use of lifelines and catheters. 
 
Detection methods of ESBL 43, 45 
There are several methods are available to detect the ESBL. Among the 
various methods some of them are discussed below. 
a. Double-disk approximation test of Tarlier  
b. Three Dimensional Test 
c. Inhibitor Potentiated Disc Diffusion Test 
d. MIC Reduction test  
e. E- test 
f. Phenotypic Confirmation Test 
g. Molecular detection methods  
 
a. Double-disk approximation test of Tarlier  
Organism is swabbed onto a Muller – Hinton agar plate. An antibiotic disk 
containing one of the Oxyimino β-lactam antibiotics placed 30mm (centre to centre) 
from the Amoxicillin –Clavulanic acid disk. Enhancement of zone of inhibition of the 
Oxyimino β-lactam caused by synergy of Clavulanate present in Amoxy-clav disk 
indicates a positive result 43, 45. 
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b. Three Dimensional test 
Advantage is simultaneous determination of antibiotic susceptibility and                     
β- lactamase substrate profile.  2 types of inoculum are prepared. 
a. Inoculum-1: contains 109 – 1010 CFU/ml of active ESBL producers. 
b. Inoculum-2: Contains 0.5 Mc Farland Std. (150 million organisms/ml) 
Plate is inoculated as for disc diffusion procedure with inoculam - 2. A 
circular slit was cut on the agar 4mm inside the position at which the antibiotic discs 
were placed and 109-1010 inoculum was poured into it.  Distortion or discontinuity in 
the circular inhibition zone is interpreted as positive for ESBL production. 
 
c. Inhibitor Potentiated Disc Diffusion test 
Cephalosporin discs are placed on MHA plates, with Clavulanate and without 
Clavulanate. More than 10mm increase in the zone of inhibition of the Clavulanate 
containing MHA plate indicates ESBL production. 
 
d. MIC Reduction test  
An eight fold reduction in the MIC of 3rd generation Cephalosporins in the 
presence of Clavulanic acid indicates production of ESBL. 
 
e. E test: 
E test ESBL strips have 2 gradients, on one end Ceftazidime and on the 
opposite end Ceftazidime plus Clavulanic acid.  MIC is the point of intersection of the 
inhibition ellipse with the E-test strip edge.  Ratio of Ceftazidime MIC and 
Ceftazidime Clavulanic acid MIC > 8 indicates presence of ESBLs. 
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g. Phenotypic Confirmation Test 
Antibiotic susceptibility testing done on Muller Hinton Agar with 0.5           
Mc Farland’s standard of the organism36. Lawn culture of the organism was made and 
3rd generation cephalosporin, Ceftazidime (30µg) disc was tested alone and along 
with their combination for 10mg of Clavulanic acid.  Organisms with 5mm increase in 
zone of inhibition for Ceftazidime / Clavulanic acid (30µg/10µg) are confirmed as 
ESBLs.  (NCCLS recommends MIC > 2µg/ml for Cefotaxime, Ceftazidime, 
Astreonam, Ceftriaxone (or) Cefpodoxime as potential ESBL producers) 43 53. 
 
Two indicators of ESBLs are  
1. 4 fold reduction in MIC when 3rd Generation Cephalosporins are used with 
Clavulanic acid. 
2. 5mm increase in diameter of inhibition zone when using disc diffusion method 
with 3rd generation Cephalosporin and Clavulanic acid combined disc. 
 
h. Molecular detection methods:  
Tests already described only presumptively identify the presence of ESBL. 
Earlier, determination of iso-electric point was sufficient for studying ESBL, But 
nowadays since there are >90 TEM type and >25 SHV type of β-lactamase and many 
of them have same iso- electric point, it has become impossible to detect the 
individual ESBLs. So detection of β-lactamases using DNA probes that were specific 
for SHV was used but they were labour intensive.  The easiest and most reliable 
molecular method used to detect ESBLs is PCR with oligonucleotide primers that are 
specific for a β-lactamase gene Oligonucleotide primers can be chosen from sequence 
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available in Gene Bank. Primers are usually chosen to anneal to regions where various 
point mutation are known to occur. 
 
Detection of Amp C β-lactamase  
a. Disc Antagonism test 
The organisms that exhibited resistance to 3rd generation cephalosporins and 
cefoxitens were swabbed onto a Muller - Hinton Agar Plate and  Cefoxiten (30  µg) 
and Ceftaxidime (30 µg) discs are placed at a distance of 20mm from centre to centre 
and incubated overnight at 37° C.  Amp C β-lactamases inducibility was recognised 
by blunting of the Ceftazidime zone adjacent to Cefoxiten disc12.  
 
b. Amp C disc test (Black et al., 2005) 46 
The test is based on the use of Tris – EDTA to permeabilize a bacterial cell 
and release β-lactamases into the external environment.  Amp C discs (i.e., filter paper 
disks containing Tris-EDTA) were prepared in house by applying 20 µl of 1:1 mixture 
of saline and 100 X Tris – EDTA to sterile filter paper discs allowing the discs to dry 
and storing them at 2- 8 °C. The surface of a MHA plate was inoculated with a lawn 
of Cefaxitin- susceptible E. coli ATCC 25922 according to the standard disc diffusion 
method.  Immediately prior to use, Amp C discs were rehydrated with 20 µl of saline 
and several colonies of each test organism were applied to a disc.  A 30 µg Cefoxiten 
disc was placed on the inoculated surface of the MHA.  The inoculated Amp C disc 
was then placed almost touching the antibiotic disc with the inoculated side of the disc 
is in contact with the agar surface.  The plate was then inverted and incubated 
overnight at 35 °C in ambient air.   
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After incubation, plates were examined for either a distortion, indicating no 
significant inactivation of Cefoxitin (positive result), or the absence of a distortion, 
indicating no significant inactivation of Cefoxitin (negative result). 
 
c. Modified three dimensional test 
Fresh overnight growth from MHA is transferred to a pre weighed sterile 
micro centrifuge tube.  The tube is weighed again to determine the weight of bacterial 
mass to obtain 10- 15mg of bacterial wet weight.  The botanical mass is suspended in 
peptone water and pelleted by centrifugation at 3000 rpm for 15 minutes.  Crude 
enzyme extract is prepared by repeated freeze thawing of bacterial pellet 
(approximately 10 cycles).  Lawn culture of E. coli A7CC 25922 is prepared on MHA 
plates and Cefoxiten 30µg disc is placed on the plates.  Linear slits (3cm) are made 
using sterile surgical blade, 3mm away from Cefoxiten disc.  All the other end of the 
slit, a small circular well is made and the extracted enzyme is loaded.  A total of 30 – 
40 ml of extract is loaded in the well at 10 µl increment.  The plates are kept upright 
for 5 – 10 m until the liquid dries and incubated at 37°C for 24 hrs.  Enhanced growth 
of the surface organism at the point where the slit inserted the zone of inhibition of 
Cefoxiten is considered a positive three dimensional test and interpreted as evidence 
of Amp C β-lactamase. 
 
Medical significance of detection of ESBL 
 Patients having infections caused by ESBL – producing organisms are at 
increased risk of treatment failure with expanded spectrum β-lactam antibiotics. So it 
is recommended that if an organism is confirmed to produce ESBL it is considered as 
resistant to all 3rd Generation Cephalosporins. 
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 Many ESBL isolates will not be phenotypically resistant; even through their 
MIC is so high. ESBL producing strains have been established in many hospitals 
producing epidemic diseases especially in Intensive Care Units  43 failure to control 
outbreaks has resulted in new mutant types in some institution. 
 
Treatment 
Carbapenems are most effective and reliable as they are highly resistant to the 
hydrolytic activity of all ESBLs due to the Trans 6 – hydroxy ethyl group.  
Alternatively, Fluoroquinolones and amino glycosides may be used if they show in 
vitro activity47. Although clinical data for their use are absent, a β- lactam and β-
lactamase inhibitor combination such as Amoxicillin-Clavulanate or Piperacillin 
Tazobactam may also be a further option to consider48.   All these agents should be 
used with caution, as their susceptibility varies among ESBL producers. Cephamycin, 
such as Cefoxitin and Cefotetan, although active in vitro are not recommended for 
treating such infections, because of the relative ease with which these strains decrease 
the expression of outer membrane proteins, rendering them resistant47.   In urinary 
tract infection combination with Clavulanic acid can be used41. 
 
Prevention and control measures 
Proper infection control practices and barrier methods are essential to prevent 
spreading and outbreaks of ESBL producing bacteria. Other practices that reduce the 
occurrence of ESBL’s are optimization of local clinical microbiological laboratories, 
the rational use of antimicrobial drugs in the community, hospital and veterinary 
settings. Support of antimicrobial surveillance programmes at local and national 
levels49.   
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MATERIALS AND METHODS 
 
Place of study  : Thanjavur Medical College Hospital, Thanjavur. 
Study period   : One year between August 2009 and July 2010 
Collaborating departments  : Medicine, Surgery, Paediatrics, Nephrology, Urology,  
  Obstetrics, Gynaecology and STD  
Design of study  : Observational study 
Ethical clearance  : Prior approval obtained from Ethical Committee 
Informed consent  : Obtained from each patient 
Inclusion criteria  : 1. Fresh case of UTI 
      2. No H/O antibiotic intake 
      3. No H/O instrumentation 
      4. No H/O immune compromised state 
       5. Non pregnant women 
      6. No H/O recent delivery 
                 7. No H/O liver or renal dysfunction 
The patients of all age groups belonging to both the sex with fever, dysurea, frequency, 
urgency, lower abdominal pain / flank pain and supra pubic tenderness that are 
suggestive of upper and lower Urinary tract infections were considered and included in 
the study. 
 
Exclusion criteria: 
Those with Diabetes mellitus and associated co-morbid conditions, promiscuous 
individual, immuno compromised status, repeated catheterization, instrumentation and 
on antimicrobial therapy were excluded.  
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Specimen collection and transport 
 Urine samples were collected in 50ml wide mouth sterile container as per CLSI 
guidelines for urine Group16-A234, 50. 
 
Midstream urine collection34 
¾ Female patients were asked to clean the area around the urethral 
opening with soap and water, and instructed to rinse well and collect 
the urine with the labia held apart. 
¾ Male patients were asked to wash periurethral region and by 
retracting the foreskin. 
¾ Patients were asked to void few ml of urine initially then collect 
about 20ml during midstream. Immediately after collection, the 
samples were labelled and transported to the laboratory and 
processed within two hours. 
 
Specimen processing 
Macroscopy34, 50 
 Urine specimen was examined macroscopically for the presence of colour and 
turbidity. 
 
Wet mount 
One drop of uncentrifuged urine was kept over a microscope slide then a cover 
slip was placed over it and it was examined under low power microscope for the 
presence of pus cells. A count of more than eight pus cells/mm3 is suggestive of 
pyuria34. 
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Gram staining 
 A drop of well mixed uncentrifuged urine was placed over the microscope slide, 
thin smear was made air dried, heat fixed and gram staining was done and examined 
under oil immersion. Presence of ≥1 to 5 bacteria / OIF was taken as significant 
bacteriuria accounts for >105 CFU/ml, presence of pus cells taken as definite indication 
of UTI34. 
 
Culture34, 51 
Uncentrifuged urine was mixed well by gently rotating the container by keeping 
it over the table. Using a calibrated loop (0.001). Each sample was inoculated in the 
following media 1. Nutrient agar, 
    2. Mac Conkey agar 
     3. Blood agar 
 Calibrated loop was flamed, after cooling it was inserted vertically into the urine to 
allow urine to adhere to the loop. And the culture plate was inoculated by keeping this 
loop in the centre of the plate and the inoculums was spread in a line on either side. 
Then without flaming, loop was drawn across the entire plate, crossing the first 
inoculum streak numerous times to produce isolated colonies. 
 
  Plates were incubated for 24 hrs at 35-37ºC. Colonies were counted on each 
plate with the help of hand lens. The number of colonies was multiplied by 1000 to 
determine the number of microorganism per ml in the original specimen.  
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Interpretation of culture34, 51  
A single type of colony was counted and interpreted as follows, 
Significant bacteriuria - More than 1, 00,000 CFU /ml.  
Probably significant’ - 10,000 -’.1, 00,000 CFU/ml – (Culture repeated) 
Insignificant - < 10,000 CFU/ml  
However, a pure culture of Staphylococcus aureus was considered to be 
significant regardless of the number of organism34. 
The isolated colony was identified by adopting the procedures of Gram staining, 
motility and routine biochemical reactions51, 52.  
  The antimicrobial sensitivity pattern for all the isolates were done in Muller 
Hinton Agar by modified Kirby – Bauer disc diffusion method as per CLSI guidelines 
using antibiotic discs (Himedia, Mumbai). 
 
Antimicrobial sensitivity testing53 
Storage of antimicrobial discs53 
 The antimicrobial disc container was refrigerated at 4 - 8° C while the β-lactum 
antibiotics were stored in the freezer compartment. Some labile agents like Imipenem 
and Clavulanic acid retained greater stability when stored frozen until the day of use. 
 Disc container was taken out from refrigerator one or two hours before use and 
brought to room temperature.  Once a cartridge of discs has been removed from its 
sealed package, after the use it was replaced in a tightly sealed dry container. 
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Preparation of turbidity standard36  
  McFarland standards prepared by adding specific volumes of 1% Suphuric acid 
and 1.175 % barium chloride to obtain a barium sulphate  solution with a specific 
optical  density.  The most commonly used is the McFarland 0.5 standard, which 
contains 99.5ml of 1% sulphuric acid and 0.5 ml of 1.175 % barium chloride.  This 
solution is dispersed into tubes comparable to those used for inoculums preparation, 
which are sealed tightly and stored in the dark at Room temp.  The McFarland 0.5 
standard provides a turbidity comparable to that of a bacterial suspension containing 
approximately 1.5 X 10 8 CFU/ml. 
 
Preparation of Inoculum 
 In order to prepare the inoculum, about 3-5 representative colonies were picked 
up and inoculated in 4-5 ml of peptone water and incubated at 37°C for 2 – 6 hrs to 
attain 0.5 McFarland’s standard which corresponds to 150 million organisms/ml.  If it 
was more turbid, then some more quantity of peptone water was added and adjusted to 
0.5 McFarland’s standard by comparing against a card with white background and 
contrasting black lines. 
Inoculation of MHA plates 
Within 15 minutes of adjusting the turbidity of the inoculum suspension, a 
sterile cotton swab was dipped and rotated several times.  During this process, the swab 
was pressed firmly on the inside wall of the tube above the fluid level to remove excess 
of broth from the swab. Then the dried surface of Muller Hinton agar plate was 
inoculated by streaking the swab over the entire sterile agar surface.  This procedure 
was repeated by streaking two more times by rotating the plates at an angle of 
approximately 60°c to ensure an even distribution of inoculums and finally, the rim of 
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the agar were swabbed. The plate was closed and left for 3-5 minutes to allow any 
excess surface moisture to be absorbed before applying drug impregnated discs. 
Application of discs to inoculated agar plates 
 The predetermined battery of antimicrobial discs of Gentamicin, Amikacin, 
Ampicillin, Cotrimaxazole, Nitrofurantoin, Nalidixic acid, Norfloxacin, Ciprofloxacin, 
Levofloxacin, Cephelexin, Cefuroxime, Cefoxitin, Ceftazidime, Ceftriaxone, 
Cefotaxim,Cefpodaxime, Cefipime, Aztreonam, Imipenam, and Amoxyclav  were 
tested for all the  isolates.  
Along with the above drugs Azithromycin and Vancomycin were tested for 
gram positive cocci. Piperacillin-Tazobactum and Cefeperazone-Sulbactum were used 
only for E. coli and klebsiella. The entire disc were placed on agar plates and pressed 
down to ensure complete contact with the agar surface.  Discs were distributed evenly 
so that they were not closer than 25 mm from centre to centre of the disc and incubated 
at 37° C for 16 – 18 hrs. 
Reading and interpretation of results 
 After 16-18 hrs of incubation, each plate was examined for satisfactory 
streaking with uniformly circular zones of inhibition and confluent lawn of growth.   
The diameter of the zones of complete inhibition including the diameter of the 
discs was measured. The zones were measured to the nearest millimetre using a ruler 
that was held on the back by inverting Petri plate.  The Petri plate was held a few inches 
above a black, non reflecting background and illuminated with reflected light.  The zone 
margin showing no obvious visible growth that could be detected with unaided eyes 
was considered as a zone of inhibition.  The sizes of the zones of inhibition were 
interpreted by referring to the CLSI standards and reported as ‘susceptible’, 
‘intermediate’ or ‘resistant’ to the drugs that were tested. 
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Table 3: ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO CLSI53 
Sl. 
No. 
Antimicrobial 
agent 
Symbol Drug concentration 
(µg) 
Zone size in mm 
Resistant Intermediate Sensitive 
A. Aminoglycosides 
1. Gentamicin  G 10 < 12 13-14 > 15 
2. Amikacin  AK 30 <14 15-16 >17 
B. Penicillin 
1. Ampicillin  A 10 <13 14-16 >17 
C. Sulphonamides 
1. Cotrimoxazole CO 1.25/23.75 <10 11-15 >16 
D. Urinary antiseptics 
1. Nitrofurantoin  NF 300 <14 15-16 >17 
E. Quinolones 
1. Nalidixic acid NA 30 <13 14-13 >19 
2. Norfloxacin NX 10 <12 13-16 >17 
3. Ciprofloxacin CF 5 <15 16-20 >21 
4. Levofloxacin LE 5 <13 14-16 >17 
F. Cephalosporins 
1. Cephelexin CP 30 <14 15-17 >18 
2. Cefuroxine CU 30 <14 15-17 >18 
3. Cefoxiten CN 30 <14 15-17 >18 
4. Ceftazidime CA 30 <14 15-17 >18 
5. Ceftriaxone CI 30 <13 14-20 >21 
6. Cefotaxime CE 30 <14 15-22 >23 
7. Cefpodoxime CEP 10 <17 18-20 >21 
8. Cefipime CPM 30 <14 15-17 >18 
G. Monobactams 
18. Aztreonam AO 30 <15 16-21 >22 
H. Carbapenems 
19. Imipenam  I 10 <13 14-15 >16 
I. β lactam - β lactamase inhibitor 
 Amoxyclav AC 20/10 <13 14 – 17 >18 
 Piperacillin-
Tazobactum 
PT 100/10 17 18 – 20 21 
 Cefeperazone-
Sulbactum 
CFS 75 / 10 15  16 20 21 
J. Macrolids 
21. Azithromycin AT 15 <13 14-17 >18 
K. Glycopeptide 
22. Vancomycin V 30 <14 ---- >15 
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Control strains used with each batch 
i. Escherichia coli ATCC 25922 
ii. Pseudomonas aeruginosa ATCC 27853 
iii. Staphylococcus aureus ATCC 25923 
 
Screening for ESBL production53 
1. Modified Kirby Bauer disc diffusion method 
Isolates showing inhibition zones <22 mm for Ceftazidme, < 27 mm for 
Cephotaxime, <25 mm for Ceftriaxone, <22 mm for Cefpodoxime and <27 mm for 
Aztreonam were identified as potential ESBL producers and they were tested further. 
 
2. Double disc synergy test53 
To demonstrate a synergistic action between a 3rd generation Cephalosporin and 
Clavulanic acid, isolates were grown and adjusted to 0.5 McFarland’s standard and 
lawn culture of it was made on MHA plate. 
Discs of 3rd generation Cephalosporin, Cefotaxime (30µg) and Ceftazidime 
(30µg) were placed 20 mm apart from an amoxicillin (20µg) and Clavulanic acid 
(10µg) combined disc (Augmentin) centre to centre and incubated at 37°C for 16 – 18 
hrs. If inhibition zone around the 3rd generation Cephalosporins showed a clear 
extension towards Augmentin disc then the organisms were said to be ESBL producing.   
 
Phenotypic confirmation test 
1. Inhibitor potentiation disc diffusion test (NCCLS confirmatory test)53 
ESBL production was confirmed by Ceftazidime (30 µg) and Ceftazidime plus 
Clavulanic acid (30 /10 µg) placed on inoculated MHA plates and incubated.  Organism  
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was considered as ESBL producer if there was ≥ 5mm increase in diameter of 
Ceftazidime/ Clavulanate disc than that of Ceftazidime disc alone.  
 
2. E-test for ESBL 43,49 
Combination of disc diffusion and Minimum Inhibitory Concentration (MIC) 
were studied using the E-test strips. The E-test strip contains Ceftazidime gradient at 
one end and Ceftazidime plus Clavulanate gradient on the opposite end.  MHA were 
inoculated as for disc diffusion and the strips were placed on the inoculated lawn and 
incubated.  MIC was the point of intersection of the inhibition ellipse with the E-test 
strip edge.  Ratio of ceftazidime MIC and Ceftazidime Clavulanic acid MIC ≥ 8 
indicated the presence of ESBL.  
 
Quality Control (QC) used for ESBL production:   
E. coli A7CC 25922 - Negative control 
Klebsiella pnemoniae ATCC 700603 – Positive control 
 
Tests for Amp C β lactamase production 
a. Disc Antagonism test12 
The organisms that exhibited resistance to 3rd generation cephalosporins and 
cefoxitins were swabbed onto a Muller - Hinton Agar Plate and  Cefoxitin (30  µg) 
and Ceftaxidime (30 µg) discs are placed at a distance of 20mm from centre to centre 
and incubated overnight at 37° C.   Amp C β-lactamases inducibility was recognized 
by blunting of the Ceftazidime zone adjacent to Cefoxitin disc12, 54. 
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b. Amp C disc test (Black et al., 2005)46 
The test is based on the use of Tris – EDTA to permeabilize bacterial cell and 
release β-lactamases into the external environment.  Amp C discs (i.e., filter paper 
disks containing Tris-EDTA) were prepared in house by applying 20 µl of 1:1 mixture 
of saline and 100 X Tris – EDTA to sterile filter paper discs allowing the discs to dry 
and storing them at 2- 8 °C.  The surface of a MHA plate was inoculated with a lawn 
of cefoxitin- susceptible E. coli ATCC 25922 according to the standard disc diffusion 
method.  Immediately prior to use, Amp C discs were rehydrated with 20 µl of saline 
and several colonies of each test organism were applied to a disc.   
A 30 µg Cefoxitin disc was placed on the inoculated surface of the MHA.  The 
inoculated Amp C disc was then placed almost touching the antibiotic disc with the 
inoculated disc face in contact with the Agar surface.  The plate was then inverted and 
incubated overnight at 35 °C in ambient air.  After incubation, plates were examined 
for either a distortion, indicating no significant inactivation of Cefoxitin (positive 
result), or the absence of a distortion, indicating no significant inactivation of 
Cefoxitin (negative result). 
 
STATISTICS: Simple descriptive statistics was used to analyse the data. 
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RESULTS 
 
The results of the present investigation on bacteriological profile, 
antimicrobial susceptibility pattern, ESBL and Amp C β- lactamase producing strains 
status with reference to Escherichia coli and Klebsiella spp in urinary tract infections 
are presented below.  
Table 4: Age and gender wise collection of samples (n = 500) 
Age Group Male % Female % Total % 
0 - 13 years 136 27.2 133 26.6 269 53.8 
15-44 years 58 11.6 87 17.4 145 29.0 
45-60 years 37 7.4 27 5.4 64 12.8 
Old age (>60 years) 14 2.8 8 1.6 22 4.4 
Total 245 49.0 255 51.0 500 100 
 
Collection of samples based on age and gender 
The data on the age and gender wise distribution of patients included in the 
study are presented in Table 4. Among the samples collected from 500 patients both 
Inpatient and Outpatients, 49% were male, 51% were female, mean age was 39 years 
with the range from new born to 78 years. The observations showed 53.8% (27.2% of 
male and female 26.6%) of the patients were less than 14 years of age. 29 % ( 11.6% 
+ 17.4%) of patients were in reproductive age group, 12.8% (7.4% + 5.4%) of patients 
from  middle age group, 4.4% ( 2.8% + 1.6% ) of patients were in older age groups 
more than 60 years. 
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Age wise distribution of patients (n= 500) 
Age and Gender wise distribution of patients (n=500) 
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Table 5:   Age and gender wise prevalence of UTI 
Age Group Male % Female % Total % 
0-13 years  26 17.3 36 24.0 62 41.3 
15-44 years 19 12.7 31 20.7 50 33.4 
45-60 years 15 10.0 8 5.3 23 15.3 
Old age (>60 years) 9 6.0 6 4.0 15 10.0 
Total 69 46.0 81 54.0 150 100 
 
Age and gender wise prevalence of UTI    
Among the 500 samples tested only 30% showed the significant bacteriuria.  
In 150 bacterial isolates 54% were from female patients and 46 % from male patients 
with a male to female ratio of 1:1.2 (Table 5). Large numbers of isolates were found 
in paediatric age group 41%  ( 17.3 % + 24 % ) followed by 33.4%  ( 12.7% + 20.7%) 
were from reproductive age group and 15.3%  (10 % + 5.3% ) from middle age and 
the rest 10% ( 6% + 4%) were from old age group.  
 
Table 6:  Department wise prevalence of UTI (n= 150) 
Department IP  OP  Total (n= 150) 
Number % Number % Number  % 
Paediatrics  52 34.6 5 3.4 57 38 
Medicine 35 23.3 5 3.4 40 26.6 
Surgery  21 14.0 2 1.4 23 15.3 
Obstetrics & gynaecology 13 8.6 2 1.4 15 10 
Urology 7 4.6 4 2.6 11 7.3 
Nephrology 2 1.3 - - 2 1.4 
STD - - 2 1.4 2 1.4 
Total 130 86.4 20 13.6 150 100 
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Age wise prevalence of UTI (n=150)
Age and sex wise prevalence of UTI (n=150)
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Department wise prevalence of UTI (n=150) 
Inpatient and outpatient wise distribution of UTI (n=150) 
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Department wise prevalence of UTI 
The data on department wise prevalence of UTI cases is presented in Table.6 
and among the 150 patients showing UTI, 130 patients i.e., 86.4% were In-patients 
and the remaining 20 patients (13.6%) were Out-patients. The department wise 
distribution of patients revealed that, the prevalence of UTI was maximum in the 
patients admitted in the department of Paediatrics which registered the highest 
number of 57 UTI cases (38%) followed by departments of Medicine (26.6%) and 
Surgery ( 15.3%). Of the 15 UTI cases in the department of Obstetrics and 
gynaecology, 13 were from in-patients and only two were from out-patients.     
Among all the departments, the departments of Nephrology and STD recorded the 
least cases of UTI (1.4% each).  
 
Table 7:  Distribution of pathogens isolated in UTI 
Sl.No Organism Frequency (n= 150) Percentage  
1. Escherichia coli 85 57 
2. Klebsiella pneumonia 21 14 
3. Klebsiella oxytoca 9 6 
4. Pseudomonas aeruginosa 4 3 
5. Proteus spp 3 2 
6. Citrobacter koseri 2 1.33 
7. Enterobacter 2 1.33 
8. Acinetobacter  3 2 
9. Staphylococcus aureus 8 5 
10. CONS 11 7 
11. Enterococcus faecalis 2 1.33 
 Total  150 100 
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Prevalence of urinary pathogens 
Isolation of the 500 samples that were collected during the study period 
indicated the presence of 150 pathogens and the details are presented in Table 7.  
Among the 150 pathogens isolated from the samples, the Gram Negative Bacilli 
(GNB) with 129 isolates (86.0%) was the major cause for UTI while only 21 isolates 
were Gram positive cocci (GPC).  Among the 129 GNB, the Escherichia coli and 
Klebsiella spp alone constituted 77 % of total isolates with 85 isolates of E. coli and 
30 isolates of Klebsiella spp. The remaining GNB isolates includes, 4 isolates of 
Pseudomonas auregenosa, 3 isolates from Proteus spp and Acinetobacter.  
Citrobacter koseri and Enterobacter accounted 2 each.  Among the 21 isolates of 
GPC, 11 were coagulase negative Staphylococcus, 8 was Staphylococcus aureus and 
2 isolates were Enterococcus faecalis. Out of 11 CONS 6 were Staphylococcus 
epidermidis and 5 isolates were Staphylococcus saprophyticus.  
 
Antimicrobial susceptibility pattern 
 A total of 150 urine samples were collected and processed for culture and 
sensitivity assay. The antibiogram revealed that, all the isolated bacteria such as 
E.coli, Klebsiella spp, Pseudomonas aurogenosa, Citrobacter, Enterobacter, 
Acinetobacter, had a maximum sensitivity pattern to Imipenum (100%) and 
Staphylococcus aureus, CONS and Enterococcus faecalis had a maximum sensitivity to 
Vancomycin(100%)  followed by Amikacin (84%), Levofloxaicin (83%), Cefepime 
(81%), Cefoxitin (76%), Nitrofurantoin (61%) and Ciprofloxacin (48%). Lower 
sensitivity pattern observed in Ampicillin (11%), 
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Table 8: Antimicrobial susceptibility pattern (number and percentage) 
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1. Gentamycin (G) 32(38) 10(33) 3(75) 1(33) 0 0 1(33) 2 (25) 4 (36) 0 53 (35) 
2. Amikacin (AK) 74(87) 26(87) 3(75) 2 (66) 2(100) 1(50) 2 (66) 6 (75) 8 (72) 0 126 (84) 
3. Ampicillin (A) 14(16) 2(7) 0 0 0 0 0 0 0 0 16 (11) 
4. Co-trimoxazole(CO) 15(18) 5(17) 0 0 0 0 0 0 0 0 20 (13) 
5. Nitrofurantoin(NF) 66(78) 19 (63) 1(25) 0 1(50) 1(50) 2 (66) 1(13) 1(9) 0 92 (61) 
6. Nalidixic acid (NA) 20 (24) 9 (30) 0 0 0 0 0 2 (25) 1(9) 0 32 (21) 
7. Norfloxacin (NX) 19 (22) 9 (30) 2 (50) 0 1(50) 1(50) 2(66) 1(13) 2(18) 0 37 (25) 
8. Ciprofloxacin (CF) 41 (48) 14 (47) 2 (50) 1(33) 1(50) 2(100) 2(66) 3(38) 6(54) 0 72 (48) 
9. Levofloxacin (LE) 73 (86) 26 (87) 3 (75) 2 (66) 2 (100) 2 (100) 2 (66) 5 (63) 9 (82) 0 124 (83) 
10. Cephalexin (CH) 15 (18) 3 (10) 0 0 0 0 0 2  (25) 2 (18) 0 22 (15) 
11. Cefuroxime (CU) 19 (22) 6 (20) 0 0 0 0 0 5 (63) 7 (64) 0 37 (25) 
12. Cefoxitin (CN) 69 (81) 21(70) 4(100) 2(66) 2(100) 2(100) 3(100) 4(50) 5(45) 1(50) 114 (76) 
13. Ceftazidime (CA) 33 (39) 11 (37) 3 (75) 3 (100) 1 (50) 0 1(33) 3 (38) 3 (27) 0 58 (39) 
14. Ceftriaxone (CI) 34 (40) 12 (40) 2 (50) 3 (100) 1 (50) 0 2 (66) 3 (38) 5 (45) 0 62 (41) 
15. Cefotaxime (CE) 37 (44) 12 (40) 1(25) 2 (66) 0 0 2 (66) 2 (25) 5 (45) 0 61 (40) 
16. Cefpodaxime (CEP) 35 (41) 11 (37) 2 (50) 3 (100) 0 0 1(33) 2 (25) 4 (36) 0 58 (39) 
17. Cefipime (CPM) 79 (93) 26 (87) 3 (75) 3 (100) 1(50) 1(50) 1(33) 3(38) 4(36) 1(50) 122 (81) 
18. Aztreonam (AO) 41 (48) 11 (37) 2 (50) 3(100) 2(100) 0 2(66) n=129 61 (40) 
19. Imipenam (I) 85(100) 30(100) 4(100) 2(66) 2(100) 2(100) 3(100) 129(100) 
20. Amoxyclav (AC) 33 (39) 13(43) 0 0 0 0 0 4(50) 5(45) 1(50) 56 (37) 
21. Piperacillin-Tazobactum  (PT) 74(87) 24(80)  n = 115 
98 (85) 
22. Cefeperazone- Sulbactum (CFS) 65(76) 23(77) 89 (77) 
23. Azithromycin(A) - 
 
- 
 
n = 21 5(63) 8(73) 1(50) 14 (67) 
24. Vancomycin (V) 8(100) 11(100) 2(100) 21 (100) 
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Antimicrobial susceptibility pattern of isolated pathogens  
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Co-trimoxazole (13%), Nalidixic acid (21%), Cephelexin (15%), Cefurioxime (25%), 
Norfloxacin (25%) and Gentamicin (35%).   
 
 Of the 85 isolates of E. coli, 57 showed resistance to anyone of the third 
generation Cephalosporins (Ceftazidime, Cefotaxime, Ceftrioxone, Cefpodoxime and 
Aztreonam).  Among the 30 isolates of Klebsiella spp 25 found resistance to the 
above drugs (Table.8).  The above isolated E.coli and Klebsiella spp were screened 
for ESBL production by Double disc synergy test. 
 
Table 9:  Prevalence ESBL and Amp C  β - lactamase 
Organism ESBL 
Amp C  
β -lactamase 
No   
β -lactamase 
Total 
 (%) 
E. coli (n=85) 47(55%) 10 (12%) 28(33%) 100 
Klebsiella spp.(n=30) 18(60%) 7 (23%) 5(17%) 100 
Total ( n = 115) 65(56%) 17(15%) 33(29%) 100 
 
The NCCLS phenotypic confirmation test and E test revealed that 55% of   
E. coli and 60% of Klebsiella isolates were found to be ESBL producer.  The rest of 
the isolates were screened for Amp C β- lactamase production by Disc antagonism 
test.  12% of E. coli and 23% of Klebsiella were confirmed Amp C β - lactamase 
producer by Amp C disc test (Table 9). Among isolated 115 E. coli and   Klebsiella 
ESBL production was found in 56% and Amp C β- lactamase production was 15%. 
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Prevalence of ESBL and Amp C Beta- lactamase  
In-patient and out-patient wise prevalence of ESBL and Amp C 
 Beta- lactamase 
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Table 10:  Inpatient and Outpatient wise prevalence of ESBL and Amp C  β -lactamase 
Organism 
ESBL 
Amp C  
β -lactamase 
No   
β -lactamase  
Total  
(%) 
IP OP IP OP IP OP  
E. coli (n=85) 42(49%) 5 (6 %) 10 (12%) 0 23(27%) 5(6%) 100 
Klebsiella spp.(n=30) 12(40%) 6(20%) 7 (23%) - 3(10%) 2(7%) 100 
Total ( n= 115) 54(47%) 11(9%) 17(15%) - 26(23%) 7(6%) 100 
 
In the present study, among the in-patients, ESBL producing E. coli was found to be 
the most prevalent organism with 49% prevalence followed by Klebsiella spp (40%). 
Whereas, in outpatients Klebsiella (20%) was the most prevalent ESBL producing 
organism followed by E. coli (6%).   Among the inpatients, the prevalence of Amp C 
β- lactamase producing E. coli and Klebsiella 12% and 23% respectively while, in 
case of outpatient, the Amp C β- lactamase production was nil.  
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Table 11: Antimicrobial susceptibility pattern of ESBL producer and non ESBL producer among isolated E. coli and Klebsiella spp. 
Organism G AK A CO NF NA NX CF LE CH CU CN CA CI CE CEP CPM AO I AC CFS PT 
E. coli 
ESBL 
producer 
n =47 
 
10 
(21) 
 
39 
(83) 
 
0 
0 
 
2 
(4) 
 
32 
(68) 
 
4 
(9) 
 
4 
(9) 
 
17 
(36) 
 
38 
(81) 
 
0 
0 
 
2 
(4) 
 
43 
(91) 
 
9 
(19) 
 
10 
 (21) 
 
12 
(26) 
 
10 
(21) 
 
43 
(91) 
 
12 
(26) 
 
47 
(100) 
 
20 
(42) 
 
43 
(91) 
 
47 
(100) 
ESBL non 
producer 
n = 28 
 
20 
(71) 
 
28 
(100) 
 
14 
(50) 
 
12 
(43) 
 
26 
(93) 
 
14 
(50) 
 
12 
(43) 
 
20 
(71) 
 
27 
(96) 
 
15 
(53) 
 
15 
(53) 
 
27 
(96) 
 
22 
(79) 
 
22 
(79) 
 
22 
(79) 
 
23 
(82) 
 
27 
(96) 
 
26 
(93) 
 
28 
(100) 
 
11 
(39) 
 
20 
(71) 
 
22 
(79) 
Amp C β 
Lactamase 
producer 
n = 10 
 
2 
( 20) 
 
7 
( 70 ) 
 
0 
(0 ) 
 
1 
(10  ) 
 
8 
(80  ) 
 
2 
( 20 ) 
 
3 
(  30) 
 
4 
( 40 ) 
 
8 
( 80 ) 
 
0 
( 0 ) 
 
2 
(20  ) 
 
0 
 (0 ) 
 
2 
( 20 ) 
2 
(20) 
 
3 
( 30 
) 
 
2 
(20  ) 
 
9 
( 90 ) 
 
3 
(30  ) 
 
10 
(100) 
 
2 
( 20 ) 
 
2 
( 20 ) 
 
5 
( 50 ) 
Klebsiella 
spp 
ESBL 
producer 
n = 18 
 
3 
(17) 
 
15 
(83) 
 
0 
0 
 
2 
(11) 
 
10 
(56) 
 
4 
(22) 
 
4 
(22) 
 
9 
( 50) 
 
16 
(89) 
 
0 
0 
 
3 
(17) 
 
16 
(89) 
 
5 
(28) 
 
6 
(33) 
 
6 
(33) 
 
5 
(28) 
 
16 
(89) 
 
6 
(33) 
 
18 
(100) 
 
9 
(50) 
 
16 
(89) 
 
17 
(94) 
ESBL non 
producer 
N =5 
 
4 
(80) 
 
5 
(100) 
 
2 
(40) 
 
3 
(60) 
 
4 
(80) 
 
3 
(60) 
 
3 
(60) 
 
3 
(60) 
 
4 
(80) 
 
2 
(40) 
 
2 
(40) 
 
5 
(100) 
 
4 
(80) 
 
4 
(80) 
 
4 
(80) 
 
4 
(80) 
 
5 
(100) 
 
4 
(80) 
 
5 
(100) 
 
2 
(40) 
 
4 
(80) 
 
3 
(60) 
Amp C β 
Lactamase 
producer 
n = 7 
 
3 
(43 ) 
 
6 
( 86 ) 
 
0 
( 0 ) 
 
0 
( 00 ) 
 
5 
(71  ) 
 
2 
(29  ) 
 
2 
(29) 
 
2 
(29) 
 
6 
(86) 
 
1 
(14) 
 
1 
(14) 
 
0 
(0) 
 
2 
(29) 
2 
(29) 
 
2 
(29) 
 
2 
(29) 
 
5 
(71) 
 
1 
(14) 
 
7 
(100) 
 
2 
(29) 
 
3 
(43) 
 
4 
(57) 
 
*. G-Gentamicin,   AK-Amikacin,   A-Ampicillin,   CO-Co-trimoxazole,   NF-Nitrofurantoin,   NA-Nalidixic acid,  
 NX-Norfloxacin,   CF-Ciprofloxacin,   LE-Levofloxacin,   CH-Cephelexin,    CU-Cefuroxime,   CN-Cefoxitin,  
 CA-Ceftazidime,  CI-Ceftriaxone,   CE-Cefotaxime,   CEP-Cefpodaxime,   CPM-Cefipime,  AO-Aztreonam,  
 I-Imipenam,   AC- Amoxyclav,   CFS-Cefeperazone-Sulbactum,     PT- Piperacillin-Tazobactum 
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Comparing the sensitive pattern of ESBL producer Vs non ESBL producer (E. coli) 
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Comparing the sensitive pattern of ESBL producer Vs Non ESBL producer 
(Klebsiella spp) 
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Comparison of the antimicrobial sensitivity pattern of ESBL producer and           
non ESBL producers  
 
In the present study Antimicrobial resistance pattern in E. coli, Klebsiella spp of 
ESBL producer and non- producer, were compared and presented in the Table 11. 
  
The ESBL producer shows multiple drug resistance than the non- ESBL 
producers.  In case of E. coli, sensitivity of Gentamicin is reduced from (71% to 21%).  
Amikacin shows (17%) reduction in sensitivity.  The co-resistance activity was found 
higher in Co- trimoxazole showing decreased sensitivity from 43% to 4%.  
Fluroquinolones also showed co-resistant pattern, sensitivity reduced in Nalidixic acid 
(50 % to 9 %), Norfloxacin (43% to 9%), Ciprofloxacin (71% to 36%) and 
Levofloxacin (96 % to 81%).  
 
Whereas, in Klebsiella spp the highest resistance was found for Gentamicin, 
sensitivity diminished from (80% to 17%).  Other drugs also showed reduction in 
sensitivity pattern in the following manner Co-trimoxozole (60% to 11%), Nalidixic 
acid (60 % to 22%), Norfloxacin (60% to 22%) and Ciprofloxacin (60% to 50%).  
 
The antimicrobial susceptibility of ESBL E. coli and Klebsiella spp to 
Imipenem, Piperacillin-Tazobactum, Cefipime, Cefoxitin, Cefeparazone-Sulbactum, 
Amikacin, Levofloxacin and Nitrofurantoin were 100%/100%, 100%/94%, 91%/89%, 
91%/89%, 91%/89%, 83/ 83%, 81/89% and 68/56% respectively. 
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The antibiotic of choice for  Amp C β- Lactamase producing E.coli and 
Klebsiella spp in UTI are Imipenam (100%/100%), Cefipime (90%/71%), 
Levofloxacin(80%/86%),  Amikacin (70%/86%) and Nitrofurantoin (80%/71%).   
 
The sensitivity of Non ESBL producing E. coli and Klebsiella for different 
antibiotics was as follows; Imipenam (100/%100%), Amikacin (100%/100%), 
Levofloxacin (96%/80%), Piperacillin-Tazobactum (79%/60%), Cefipime 
(96%/100%), Nitrofurantoin (93%/80%), Cefeperazone-Sulbactum (71%/80%), 
Cefoxiten (96%/100%) Aztreonam (93%/80%) and 3rd generation Cephalosporins like 
ceftazidine, ceftrioxone, cefotoxime (79%/80%) and cefpodoxime (82%/80%). 
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DISCUSSION 
Urinary tract infections (UTI) are the most common bacterial infection among 
the humans. Perhaps one of the most important factors impacting the management of 
UTI over the past decade is emergence of anti microbial resistance among 
uropathogens.55 Production of ESBLs and Amp C β-lactamases are the most common 
mechanism of anti microbial resistance in gram negative bacteria. A prospective study 
was under taken to know the occurrence of ESBL, Amp C β-lactamases producing 
strains and their anti microbial susceptibilities to newer agents to guide therapy for 
urinary tract infection. 
During the neonatal period about one per cent of all babies have bacteria in 
bladder urine then up to three months UTI is more common in male babies after that 
UTI predominates in females of all age groups. Again after 60 years UTI incidence 
increases in males36. 
 In the present study 500 samples were collected from MSU. Among the 
samples 150 (30%) showed significant growth of bacteria. According to Chua et al. 
(1988)56 in Philippines, the clean-catch midstream urine collection is primarily aimed at 
avoiding contamination of voided urine by urethral and perineal flora, which might 
confuse the interpretation of culture results.  The normal urethral flora consists 
primarily of diphtheriods, streptococci and staphylococci30.  In contrast, Morris et al. 
(1979)57concluded that in ambulant adult perineal cleansing before voided urine sample 
is taken does not influence the bacteriologic finding.   In a study, Turner (1961)58 on 
pregnant women, demonstrated that vulvar cleansing did not decrease the 
contamination rate of midstream voided specimen.  It is also probable that in some 
instance, the use of disinfectant and antiseptics in the cleansing procedure might alter 
and decrease the true bacterial count. 
75 
 
Sex and Age wise prevalence of UTI 
Significant bacteriuria showed in 30% of 500 tested samples. Out of 150 
bacterial isolates 46% were males and females were 54% with the male to female ratio 
of 1:1.2. Similar finding (1:1.3) was shown by Baby padmini and Appala Raju (2004)14 
in Tamil Nadu.  According to Foxman et al. (2003)35, USA the ratio was 1:4.2.  In 
every age group there was a higher incidence of UTI in adult female than male with an 
annual incidence of 12.6% in women as compared with 3% among men. Incidence of 
UTI is higher in females because of the shorter urethra that bacteria have less distance 
to travel to reach the bladder.  In addition, the urethral meatus opens into the moist 
introitus which is colonized by bacteria have the potential to cause cystitis. Sexual 
intercourse, pregnancy and post menopausal state also favours occurrence of UTI in 
females29.  
In the present study, more number of UTI were found in paediatric age group of 
41.3%, followed by 33.3% were from reproductive age,15.3% were in middle age and 
elderly accounts for 10%.   Bacteriuria is common in association with UTI in male 
newborns.  When infection occurs in pre-school boys, it is frequently associated with 
serious congenital abnormalities.  The prevalence of significant bacteriuria in this age 
group is 4.5% for girls and 0.5% for boys.  About one third of these patients had some 
referable urinary tract abnormality when bacteriuria was first detected.  The presence of 
bacteriuria in childhood defines a population at higher risk for development of 
bacteriuria in adult.  ESBL producing E. coli may be causative agent of UTI in children 
without any specific risk factor59. The similar findings showed in which the prevalence 
of bacteriuria in adult men is low (0.1% or less).  In young men, a lack of circumcision 
may also increase the risk for UTI caused by uropathogenic strain of E. coli including 
the development of symptomatic urethritis60.     
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Department wise prevalence of UTI 
In the present study, the results on the department wise prevalence of UTI found 
to be highest in paediatric and followed by medicine.  But, in the study by Ullal et al. 
(2009)61 Pakistan, patients from gynaecology contributed maximum number of isolates 
(42.2%) followed by medicine department as in the case of the present study. 
Table 12: Comparision of Common organisms causing UTI 
Organisms   Latin America49 India7  Tamilnadu78  Present study 
E. coli 60.4% 61% 30.2% 57% 
Klebsiella 11.1% 22% 22% 20% 
Pseudomonas 8.3% 4% 12.35% 3% 
Acinetobacter 10% 3% 8.3% 2% 
Proteus 4.6% - 6.7% 2% 
Enterobacter 14% - 35% 1.3% 
Citrobacter 7% 2% 2.5% 1.3% 
CONS - 7% 5% 7% 
Enterococcus 2.3% 1% 9.5% 1.3% 
 
 In the present study, E. coli (57%) was the commonest organism isolated 
followed by Klebsiella (20%), CONS (7%) and the least isolated was Citrobacter, 
Enterobacter, Enterococcus each accounting 1.3%. The study conducted in India by 
Akram et.al (2007)7 and in Latin America by Ana.C.Gales et.al (1998) 49 showed that 
the E. coli was the commonest organism isolated followed by Klebsiella. In this study 
7% of CONS were isolated and the same was found in Akram et.al (2007) 7. In the 
present study, only 1.3% of Enterococcus was isolated, but the study conducted by 
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Ana.C.Gales et.al (1998) 49 showed the highest isolation of about 14% and Ramesh 
et.al (2008) 78 Tamil Nadu showed 9.58% of isolation.  
 
Table 13: Comparison of E. coli isolates among UTI in various part of the world 
Sl.No. 
Name of the 
Country/ State 
E. coli (%) Reference 
A International  Sana et al. (2005)63 
1. Israel 94 
1. USA 90  
2. Kuwait  90  
3. England  75  
4. Sweden  74  
5. Italy  69  
6. Japan  65  
B National    
1. Kashmir 90 Chatterjee et al. (2009)65 
2. Maharashtra   83.4 Chatterjee et al. (2009) 65 
3. Tamil Nadu 49.3 Baby Padmini and Appalaraju (2004)14 
4. New Delhi  46 Mohanty et al. (2005)64 
5. Present study  57  
 
E. coli was the predominant pathogen isolated from patients with community 
acquired UTI11, 62.   Among the 500 samples obtained, 150 pathogens were isolated and 
129 out of them were Gram negative bacilli were the leading cause of UTI followed by 
Gram positive cocci with 21 isolates.  A higher isolate rate was reported by 61 % 
reported by Akram et al., (2007)7, but lower isolate rate of 43.5% reported by Sana et 
al., (2005)63 in Kuwait and 46 %  E. coli by Mohanty et al. (2005) 64 in New Delhi.  
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While seeing the current status of UTI, in worldwide studies have revealed a 
preponderance of E .coli in urinary isolates 65% in Japan, 69 % in Italy, 74 % in 
Sweden, 75 %    in England up to 90 % in USA and as high as 94 % in Israel.63     
 
Antibiotic susceptibility pattern 
The most effective antibiotics against all isolates were Imipenam (100%) 
followed by Amikacin (84%), Levofloxacin (83%), Cefepime (81%), Cefoxitin (76%), 
Nitrofurantoin (61%) and Ciprofloxacin (48%).  However, Akram et. al. (2007)7 from 
India have reported 100% activity of Imipenem against E. Coli and similar findings 
were also reported by Ullal et. al. (2009) from Pakistan61. 
Both Ampicillin and Co-trimoxazole were highly resistant shows only 11% and 
13% sensitivity.  Studies from USA, Europe and most other countries have shown 
better susceptibility pattern for pathogens isolated from UTI against Co-trimoxazole66, 
67, 68, 69.  But, in this region of the world Co-trimoxazole has shown poor activity15, 7.  A 
reason for this lack of sensitivity may be that in the past, Co-trimoxazole has been 
extensively used in this region.  Among the 85 E. coli, 70 (82.4%) strains were resistant 
to Co-trimoxazole.  Hence, Co-trimoxazole cannot be recommended as an empiric 
therapy for the treatment of UTI in India. Rest of the antibiotics were resistant to all the 
isolated pathogen by 50% and more.   
 
Prevalence of ESBL production  
The NCCLS phenotypic confirmation test and E test revealed that out of 85 
isolates of E. coli, 47 (55%) were found to be ESBL producer, out of 30 isolates of 
Klebsiella, 18 (60%) were found to be ESBL producer.   
79 
 
Whereas, lower occurrence of ESBL  producer in urinary isolates of E. coli and 
Klebsiella was found to be 40 and 41 % respectively as reported by Baby Padmini and 
Appalaraju, 200414 Coimbatore.   
This was higher than the reported figures of E. coli and Klebsiella in USA 
(2.2/6.6%), Canada (2.7/ 6.2%) and India (24.7 /38.5%) by Sumeeta et al., (2002)70  
Much higher prevalence of ESBL producers (E. coli 60% and Klebsiella 44%) in 
urinary isolates of Gram negative bacilli was observed in Norway by Toftelan (2007)71 
and  70% of E. coli and 54.5% Klebsiella was observed in India (Purva et al., 2002)72. 
Study conducted at Mangalore by Beena Antony et al. (2010)73 showed the prevalence 
of 70% and 75% of E. coli and Klebsiella spp respectively producing ESBL. 
 
Table 14: ESBL production among E. coli and Klebsiella from various 
geographical areas 
S.No Geographical  
area 
E. Coli 
(%) 
Klebsiella 
(%) 
Reference 
1. USA  2.2 6.6 Sumeeta et al., 200270 
2. Canada  2.7 6.7 Sumeeta et al., 200270 
3.  Norway  60 44 Sumeeta et al., 200270 
4. Europe  5.3 22.6 Calbo et al., 200674 
5. Pakistan  51 40 Mumtaz, 200675 
6.. India  70 54.5 Singhal et al.,2076 
7.. Manipal 35 41 Shoba et al.,200777 
8.  Mangalore,  70 75 Beena Antony et al., 201073 
8. Nagpur  34 25.6 Tankiwale et al., 200415 
9. Kerala 62.3 67.4 Sashikala et al., 201048 
10. Tamil Nadu 41 40 Baby Padmini and Appalaraju, 200414 
11. Present study 55 60  
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Prevalence of Amp C β- lactamase 
In the present study, the prevalence of Amp C β- lactamase producer was lesser 
among E. coli (12%) as compared to the 23% prevalence among Klebsiella. This is in 
accordance with the findings of Ramesh et al (2008)78 from Tamil Nadu who had 
recorded lesser prevalence of Amp C β- lactamase in E. coli (9.9%) and more among 
Klebsiella (31.1%). In contrast, under Mangalore conditions Beena Antony et al. 
(2010)37 recorded much higher production of Amp C β- lactamase among E. coli (15.4 
%) than in Klebsiella (5.4 %). However, Singhal et al. (2005)76 recorded almost equal 
production of Amp C β- lactamase both among E. coli (6.97%) and Klebsiella (6.18%).  
 
Inpatient and outpatient wise prevalence of ESBL and Amp C β- lactamase 
In the present study, among the in-patients, ESBL producing E. coli (49%) was 
found to be most prevalent organism followed by Klebsiella spp (40%).  While in 
Outpatients Klebsiella (20%) was the most prevalent ESBL producing organism, 
followed by E. coli (6%). A similar finding was observed by Mumtaz (2006) in 
Pakistan75.  According to Calbo et al. (2006) in Europe, prevalence of infection due to 
ESBL producing E. coli in UTIs increased from 0.4 % to 1.7 % in the span of 3 years.  
Community onset ESBL producing E. coli infection shifted from 50% too 79.5 % 
within the period of 3 years from 2000 to 200374. According to Pena et al., 2006 from 
Barcelona, Spain, 68% of the hospitalized patients develop infection, yielding one or 
more clinical isolates of ESBLs producing E. coli.  A significant increase was observed 
the incidence of ESBL producing E. coli colonization or infection during the study 
period21.   
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Another study showed that among hospitalized patients, the most prevalent 
ESBL producer was Klebsiella followed by E. coli.  A study by Luzzaro et al. (2006) in 
Italy and Lin et al. (2006) in Taiwan, showed that ESBL producing E. coli were 16.3 % 
from Outpatients79,80. 
 Among the inpatients Amp C β- lactamase producing E. coli was 12% and 
Klebsiella was 23% but in case of out patient Amp C β- lactamase production was 
found to be nil. Singhal et al., 200576 also reported that in outpatients, out of 74%  of 
Klebsiella and 62% of E. coli UTI isolates, the Amp C β- lactamase production  was 
nil. It has been reported that at present in India Amp C β- lactamase harbouring isolates 
are largely restricted to the hospitalised patients only76. 
ESBLs are now a problem in hospitalized patients throughout the world.  The 
prevalence of ESBLs among clinical isolates varies greatly worldwide and in 
geographical areas and are rapidly changing over time81.  
 
Co-resistance pattern of ESBL producers 
The ESBL producer shows multiple drug resistance than the non- ESBL 
producers.  In case of E. coli, sensitivity of Gentamicin is reduced from 71 % to 21 %.  
Whereas Amikacin shows 17% reduction in sensitivity.  The co-resistance activity was 
found higher in Co- trimoxazole showing decreased sensitivity from and for E. coli   
(43 % to 4 %).  Fluroquinolones also shows co- resistance pattern, Sensitivity reduced 
in Nalidixic acid (50% to 9%), Norfloxacin (43% to 9%), Ciprofloxacin (71 % to 36 %) 
and Levofloxacin (96 % to 81%).   Whereas, in Klebsiella spp the highest resistance 
was found in Gentamicin, sensitivity diminished from (80% to17 %).  Other drugs 
shown to be resistance are Co-trimoxazole (60% to 11%), Nalidixic acid (60% to 22%), 
Norfloxacin (60% to 22%) and Ciprofloxacin (60% to 50%).  
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Genes coding for resistance to β - Lactam antibiotics and Quinolones are 
located on the same plasmid and thus passed on together among different 
Enterobacteriaceae, in addition loss of outer membrane proteins (or) efflux pump over 
expression plays a major role in co-resistance82.       
Genes that encode resistance to Aminoglycosides and Co- trimoxazole are 
located on a wide range of genetic elements such as class 1, 2, and 3 integrons or 
transposable elements have been associated with different multidrug resistant ESBL 
plasmids from human and animal origin74. 
In contrast, at Mangalore higher resistance was observed in Co- trimoxazole (84 
-100%), Gentamicin (40 – 93%), Ciprofloxacin (91 – 100%) by Beena Antony et al. 
(2010)73.  In our study, the resistance to Fluoroquinolones varied from 9 – 41% for 
various organisms.  In contrast, 27.6 to 90% of resistance was observed at Bangalore by 
Mahesh et al. (2010).  Gordon et al. (2003)83, 68 reported Quinolones as the most active 
against UTI pathogens in North America.   Peterson et al. (2007) have reported a 
resistance rate of 5- 20% in their study in USA84. 
    In our study, 32% of the E. coli and 33% Klebsiella isolates only sensitive to 
Gentamicin. The co-resistance was comparatively low for Amikacinf (17%).  Similar 
findings were observed by Baby Padmini and Appalaraju (2004)14.  
Co-Resistance was high in Amp C β- Lactamase producers than ESBL 
producers. Among the Amp C β- Lactamase producers, the Aminoglycosides showed 
the highest resistance followed by Cotrimoxazole and fluroquinolones. 
 
Sensitivity to β - Lactam and β - Lactamase inhibitor in ESBL producers 
In the present study, the ESBL producing E. coli and Klebsiella showed 100% 
and 94% sensitivity to Piperacillin-Tazobactum respectively followed by 91% and 89% 
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sensitivity against Cefeperazone-Sulbactum. A similar finding was reported by 
Shasikala et al. (2010)48 in Kerala that E. coli exhibited 96.80% and 93.3% sensitivity 
to Piperacillin-Tazobactum and Cefeperazone-Sulbactum.   
Whereas in Mangalore, Shigu et al. (2010)85 showed 100% sensitivity of the 
ESBL  producing E. coli and 98% and 88% sensitivity of the ESBL producing  
Klebsiella to Piperacillin-Tazobactum and Cefeperazone - sulbactum respectively. 
 
Antibiotic of choice for ESBL producing E. coli and Klebsiella spp 
The present study revealed that the most effective antibiotic against ESBL 
producing E. coli, and Klebsiella spp. in UTI are Imipenam (100/100%), Piperacillin-
Tazobactum (100%/94%), Cefipime (91%/89%), Cefeperazone-sulbactum (91%/89%), 
Cefoxiten (91%/89%) Amikacin (83%/83%), Levofloxacin (81%/89%) and 
Nitrofurantoin (68/%56%). Baby Padmini and Appalaraju, (2004)14 and Tankhiwale, 
(2004)15 suggested Imipenam (100%), Nitrofurantoin (89%) and Amikacin (86%) is the 
drug of choice for ESBL producers which are similar to this study. 
Study conducted in Kerala by (Shasikala et al., 2010) showed Piperacillin-
Tazobactum (96.8%), Cefeperazone-sulbactum (92.2%), were sensitive to ESBL 
producers48. 
 
Antibiotic of choice for Amp C β- Lactamase producing E. coli and Klebsiella spp 
The antibiotic of choice for Amp C β- Lactamase producing E. coli and 
Klebsiella spp in UTI are  Imipenam (100/100%), Cefipime (90%/71%), Amikacin 
(70%/86%), Levofloxacin (80%/86%) and Nitrofurantoin ( 80%/71%). It is comparable 
with Neelam Taneja (2006) India12 and Zanetti et.al (2003) 86 both of them suggests 
carbapenam are more effective than cefipime. Amp C β- Lactamases are clinically 
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important because they confer resistance to Extended spectrum 
Cephalosporins,Cephamycins,Monobactums β - Lactam and β - Lactamase inhibitor 
combinations12. 
Imipenam resistant organisms were isolated in different hospitals in India which 
was widely discussed as Super bug in press and parliament (Lancet, 2010)87.  During 
the present study, no resistance was noticed to Imipenam.  Imipenam should be used as 
the second line of drug to prevent further resistance and rest of the drugs can be used as 
the first line of choice. The routine susceptibility testing by clinical laboratories fail to 
detect ESBL positive strains and shows false invitro sensitivity to Cephalosporins. 
Screening for ESBL and Amp C β- Lactamase production as a routine procedure in 
clinical laboratories gives valuable information to the clinician in appropriate selection 
of antibiotics.  
 
Limitation of the study    
1. Single centred study 
2. Follow up of cases not done 
3. Due to technical constraints the studies were limited to phenotypic methods 
only. 
 
Strength of the study  
1. Strict criteria for case selection 
2. Samples were collected and processed by single person 
3. Processing was carried out within shortest time. 
4. Quality control maintained 
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Suggestions 
1. Avoiding  indiscriminate use of antibiotic by ensuring that the indication for, and 
the dose and duration of treatment are appropriate, 
2. Restricting the use of antimicrobial combinations to appropriate circumstances, 
3.  Constantly monitoring the resistance patterns in a hospital or community and 
change recommended antibiotics used for empirical treatment and limiting the 
newest group of antimicrobials as long as the current drugs are effective. 
4. Maintenance of infection control in hospitals, such as the isolation of carriers, 
hand hygiene practices for ward staff prevent the spread of resistant bacteria. 
5. Restricting the use of catheter, if needed it should be carried out with all strict 
aseptic precaution.   
6. Conducting periodic educational programme on antimicrobial use for the 
practitioner in order to limit the use and to minimize the antibiotic resistance 
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SUMMARY AND CONCLUSION 
The study was conducted at Thanjavur Medical College Hospital, Thanjavur 
over a period of one year from 1st August 2009 to 30th July 2010 with 500 patients 
suffering from UTI, which included 49 % of males and 51 % of females. Among 500 
patients 150 (30%) of them had significant bacteriuria.  UTI was higher in paediatric 
age groups 41.3% followed by reproductive age group (33.3%).     
¾ In this study, 129 Gram Negative Bacilli and 21 Gram Positive Cocci were 
isolated among which E. coli (57%) was the commonest organism isolated 
followed by Klebsiella spp 20%, Pseudomonas aeruginosa 3%, Proteus 2%, 
Enterobacter and Citrobacter Koseri each accounting1.35 %  and Acinetobacter 
2%. Among the Gram Positive cocci, 7% were CONS, 5% were Staphalococcus 
aureus and 1.3% were Enterococcus  faecalis. 
¾ All the Gram negative bacilli were mostly sensitive to Imepenam (100%) and 
Gram positive cocci were sensitive to vancomycin (100%) followed by 
Amikacin (84%), Levofloxacin (83%), Cefipime (81%), Cefoxitin (76%), and 
Nitrofurantoin (61%).    
¾ Prevalence of ESBL production was found in 55 % of the E. coli and 60 % of 
the Klebsiella spp.  
¾ Prevalence of Amp C  β lactamase production was 12 % in E.coli and 23% in 
Klebsiella spp. 
¾ ESBL producing strains showed multiple drug resistance than the non ESBL 
production.  The ESBL producing E. coli and Klebsiella showed highest 
resistance to Gentamicin, Co-trimoxazole, Nalidixic acid, Norfloxacin and 
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Ciprofloxacin. Low level of resistance was seen in Nitrofurantoin, Amikacin 
and Levofloxacin.   
¾ The sensitivity pattern of ESBL E. coli and Klebsiella spp are Imipenem (100 
%/100%), Piperacillin-Tazobactum (100%/94%), Cefipime (91%/89%), 
Cefoxitin (91%/89%), Cefeperazone-Sulbatum (91%/89%), Amikacin 
(83%/83%), Levofloxacin (81% / 89%) and Nitrofurantoin (68% / 56%).   
¾ The antibiotic of choice for Amp C β Lactamase producing E. coli and 
Klebsiella spp in UTI are Imipenam (100%/100%), Cefipime (90%/71%), 
Amikacin (70%/86%), Levofloxacin (80%/86%) and Nitrofurantoin (80%/ 
71%).   
 Even though all the isolates are 100% sensitive to Imepenam, it should be kept 
in reserve as the second line of drug.  Other drugs which is most economic and orally 
effective like Nitrofurantoin and Levofloxacin can be given to outpatients.  Amikacin, 
Cefipime and β lactamase Inhibitors Piperacillin-Tazobactum, Cefeperazone- Sulbatum 
can be given to inpatients.  
Based on our study, we conclude that, there is a high prevalence rate of ESBL 
and Amp C β- Lactamase production seen among uropathogenic E. coli and Klebsiella 
spp.  Based on the prevalence rate of the ESBL and Amp C β- Lactamase production in 
a health care facility, institutional antibiotic policy can be tailored to achieve superior 
therapeutic outcome and bring about a reduction in healthcare costs. It also eliminates 
misuse of conventional cephalosporin in a significant proportion of patients. Drug 
resistance pattern varied from place to place which may be related to the nature of the 
pathogen and preferred antimicrobial agents.  
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INFORMED CONSENT 
 
I have been informed about the study of Urinary Tract Infection.  I totally agree 
to participate in the study, as I realize the importance of the study.  I also aware that I 
can withdraw from the study whenever like. 
 
 
Date  :                Signature of 
the patient 
Department :        
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PROFORMA 
 
Name:      Serial No: 
Age:      Lab No: 
Sex:      OP/IP No: 
Education:     D.O.A: 
Occupation:     D.O.D: 
Income:     Provisional Diagnosis: 
Address: 
Chief complaints: 
   Fever 
   Dysurea  
   Frequency    
   Urgency   
   Lower abdominal/ flank pain 
H/O Present illness: 
Associated conditions- instrumentation/ surgery in urinary tract 
   Calculi  
   Diabetes mellitus 
   Chronic kidney and liver diseases 
   Benign Prostatic Hypertrophy 
   Pregnancy 
 Immuno compromised state 
Treatment History:  H/O anti biotic intake, duration  
Past History:          H/O Similar episode in the past  
    Instrumentation/ surgery in urinary tract 
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Family History: 
Personal History: 
General Examination: Stature, nourishment, anaemia, jaundice, cyanosis, clubbing, 
     lymphadenopathy, pedal edema.  
Vital signs:  Temperature, pulse rate, respiratory rate, blood pressure. 
Systemic examination: Abdomen  
Inspection:  shape of the abdomen  
   Position of the umbilicus 
   Movements of the abdominal wall 
   Skin and surface of the abdomen  
Palpation  : Mass  
    Tenderness (Suprapubic) 
   Rigidity  
   Organomegaly 
Percussion   : Any free fluid  
Auscultation  : Bowel sounds  
     Bruit 
Examination of groin and genital region  
P/V: 
P/R: 
Examination of other systems  
CVS: 
RS; 
CNS:   
Definitive Diagnosis 
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WORKSHEET 
 
Specimen:    Urine  
Method of collection : MSU/Indwelling catheter/Cystoscope/Suprapubic 
aspiration 
I. Macroscopic Examination: Color  
    Turbidity 
II. Microscopic Examination: Wet mount  
    Gram staining 
III. Culture    : Nutrient agar 
       MacConkey agar 
       Blood agar 
IV. Biochemical Reactions: 
Gram staining   : 
Motility   : 
Catalase   : 
Oxidase   : 
Sugar fermentation tests : 
IMViC    : 
Urease    : 
TSI    : 
LAO    :      Special 
Tests: 
Coagulase    : 
Micro organism isolated : 
V. Anti Microbial Susceptibility test: 
VI. Screening for ESBL :  1. Antibiogram 
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   2. Double disc synergy test  
VII. Conformation of ESBL   : 1. Double disc potentiation 
       2. E Test  
Screening for Amp C β-lactamases: 1. Cefoxitin resistant strains 
               2. Double disc antagonism test 
Confirmation for Amp C β-lactamases: Amp C disc test 
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